At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
In Brief
A Phase 3 clinical trial evaluating Durvalumab, Placebo, and 5 other interventions for Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 328 participants across 86 sites in 14 countries.
Detailed Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care \[SoC\] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).
Study Details
Timeline
Interventions
Durvalumab IV (intravenous infusion)
Placebo IV (intravenous infusion)
Cisplatin/ Etoposide, as per standard of care
Carboplatin /Paclitaxel, as per standard of care
Pemetrexed / Cisplatin, as per standard of care
Pemetrexed / Carboplatin , as per standard of care
5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)